Towards conformational fidelity of a quaternary HIV-1 epitope: computational design and directed evolution of a minimal V1V2 antigen
暂无分享,去创建一个
Chris Bailey-Kellogg | Deeptak Verma | C. Bailey-Kellogg | M. Ackerman | Deeptak Verma | Margaret E Ackerman | Jennifer I Lai | Jennifer I. Lai
[1] K. Wittrup,et al. Highly avid magnetic bead capture: An efficient selection method for de novo protein engineering utilizing yeast surface display , 2009, Biotechnology progress.
[2] David Baker,et al. Proof of principle for epitope-focused vaccine design , 2014, Nature.
[3] Alexandre G. de Brevern,et al. Protein Peeling 3D: new tools for analyzing protein structures , 2011, Bioinform..
[4] D. Baker,et al. RosettaRemodel: A Generalized Framework for Flexible Backbone Protein Design , 2011, PloS one.
[5] Adrian Apetri,et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen , 2015, Science.
[6] S. Zolla-Pazner,et al. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits , 2016, Journal of Virology.
[7] Allan C. deCamp,et al. HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees , 2018, Journal of Virology.
[8] Karen G. Dowell,et al. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles , 2017, Journal of immunological methods.
[9] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[10] Guido Ferrari,et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.
[11] John P. Moore,et al. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[12] A. Pinter,et al. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains , 1994, Journal of virology.
[13] E. Go,et al. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. , 2008, Journal of proteome research.
[14] K Dane Wittrup,et al. Isolating and engineering human antibodies using yeast surface display , 2006, Nature Protocols.
[15] Gevorg Grigoryan,et al. Rapid search for tertiary fragments reveals protein sequence–structure relationships , 2015, Protein science : a publication of the Protein Society.
[16] Baoshan Zhang,et al. Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 , 2013, Nature Structural &Molecular Biology.
[17] D. Baker,et al. Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold , 2011, Science.
[18] John P. Moore,et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9 , 2013, Proceedings of the National Academy of Sciences.
[19] Raphael Gottardo,et al. Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial , 2013, PloS one.
[20] J. Sodroski,et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.
[21] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[22] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[23] C. Bailey-Kellogg,et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.
[24] Serge A. Hazout,et al. 'Protein Peeling': an approach for splitting a 3D protein structure into compact fragments , 2006, Bioinform..
[25] John P. Moore,et al. Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.
[26] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.
[27] Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody. , 2016, Molecular immunology.
[28] Eric T. Boder,et al. Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.
[29] R. Wyatt,et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. , 2015, Cell reports.
[30] S. Zolla-Pazner,et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. , 2012, Virology.
[31] D. van der Spoel,et al. GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .
[32] Timothy Cardozo,et al. Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design , 2010, Nature Reviews Immunology.
[33] J. Mascola,et al. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry , 1995, Journal of virology.
[34] William R Schief,et al. Advances in structure-based vaccine design. , 2013, Current opinion in virology.
[35] M. Ackerman,et al. Directed Evolution of a Yeast-Displayed HIV-1 SOSIP gp140 Spike Protein toward Improved Expression and Affinity for Conformational Antibodies , 2015, PloS one.
[36] R. Rappuoli,et al. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design , 2016, The Journal of experimental medicine.
[37] Gary J. Nabel,et al. Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection , 2014, PloS one.
[38] Cinque S. Soto,et al. Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.
[39] What mAbs tell us about shapes: multiple roads lead to Rome. , 2013, Immunity.
[40] Jonathan R. McDaniel,et al. Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design , 2015, Nature Structural &Molecular Biology.
[41] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[42] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[43] S. Zolla-Pazner,et al. Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals. , 1997, AIDS.
[44] John P. Moore,et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.
[45] P. Plateau,et al. Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction. , 1995, Analytical biochemistry.
[46] D. Burton,et al. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles , 2016, Nature Communications.
[47] J. Sodroski,et al. Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins , 2002, Journal of Virology.
[48] Jerome H. Kim,et al. Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family , 2012, Journal of Virology.
[49] Guido Ferrari,et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. , 2013, Immunity.